MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer

Carcinogenesis

Volumn 31, Issue 12, 2010, Pages 2118-2123

  Zhang, Xiaofan ^a   Yang, Hushan ^a   Jack Lee, J ^a   Kim, Edward ^a   Lippman, Scott M ^a   Khuri, Fadlo R ^b   Spitz, Margaret R ^a   Lotan, Reuben ^a   Hong, Waun K ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ARTICLE; BINDING SITE; BIOGENESIS; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHILD; EARLY CANCER; EVENT FREE SURVIVAL; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEAD AND NECK CANCER; HIGH RISK POPULATION; HOMOZYGOTE; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; PREDICTOR VARIABLE; PRESCHOOL CHILD; PRIORITY JOURNAL; SECOND CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME;

CELL CYCLE PROTEINS; CHROMOSOMAL PROTEINS, NON-HISTONE; GENETIC VARIATION; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; KARYOPHERINS; MICRORNAS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 78649802554     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq177     Document Type: Article

References (46)

1. Wu,X. et al. (2006) Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin. Cancer Res., 12, 7194-7201.
2. Wu,X. et al. (2009) Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev. Res. (Phila. Pa), 2, 617-624.
3. Jemal,A. et al. (2009) Cancer statistics, 2009. CA Cancer J Clin., 59, 225-249.
4. Braakhuis,B.J. et al. (2002) Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck, 24, 198-206.
5. Cooper,J.S. et al. (1989) Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int. J. Radiat. Oncol. Biol. Phys., 17, 449-456.
6. Do,K.A. et al. (2003) Second primary tumors in patients with upper aero-digestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control, 14, 131-138.
7. Haughey,B.H. et al. (1992) Meta-analysis of second malignant tumors in head and neck cancer: the case for an endoscopic screening protocol. Ann. Otol. Rhinol. Laryngol., 101, 105-112.
8. Khuri,F.R. et al. (2001) The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol. Biomarkers Prev., 10, 823-829.
9. Spitz,M.R. et al. (2003) Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol. Biomarkers Prev., 12, 689-698.
10. Wu,X. et al. (2004) Genetic susceptibility to tobacco-related cancer. Oncogene, 23, 6500-6523.
11. Lu,J. et al. (2005) MicroRNA expression profiles classify human cancers. Nature, 435, 834-838.
12. Calin,G.A. et al. (2005) A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med., 353, 1793-1801.
13. Yanaihara,N. et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9, 189-198.
14. Subramanian,S. et al. (2008) MicroRNA expression signature of human sarcomas. Oncogene, 27, 2015-2026.
15. Wang,T. et al. (2007) A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer, 46, 336-347.
16. Yu,S.L. et al. (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell, 13, 48-57.
17. Yu,S.L. et al. (2007) Unique microRNA signature and clinical outcome of cancers. DNA Cell Biol., 26, 283-292.
18. Sun,B.K. et al. (2008) Small RNAs in development and disease. J. Am. Acad. Dermatol., 59, 725-737; quiz. 738-40.
19. Kusenda,B. et al. (2006) MicroRNA biogenesis, functionality and cancer relevance. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub., 150, 205-215.
20. Faller,M. et al. (2008) MicroRNA biogenesis: there's more than one way to skin a cat. Biochim. Biophys. Acta., 1779, 663-667.
21. Gregory,R.I. et al. (2006) MicroRNA biogenesis: isolation and characterization of the microprocessor complex. Methods Mol. Biol., 342, 33-47.
22. Tomari,Y. et al. (2005) MicroRNA biogenesis: drosha can't cut it without a partner. Curr. Biol., 15, R61-R4.
23. Gregory,R.I. et al. (2005) Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell, 123, 631-640.
24. Gregory,R.I. et al. (2005) MicroRNA biogenesis and cancer. Cancer Res., 65, 3509-3512.
25. Horikawa,Y. et al. (2008) Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin. Cancer Res., 14, 7956-7962.
26. Yang,H. et al. (2008) Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res., 68, 2530-2537.
27. Ye,Y. et al. (2008) Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev. Res. (Phila. Pa), 1, 460-469.
28. Christensen,B.C. et al. (2009) A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers. Carcinogenesis, 30, 1003-1007.
29. Mishra,P.J. et al. (2007) A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl Acad. Set USA, 104, 13513-13518.
30. Steemers,F.J. et al. (2006) Whole-genome genotyping with the single-base extension assay. Nat. Methods, 3, 31-33.
31. Zhang,X. et al. (2009) Alterations in miRNA processing and expression in pleomorphic adenomas of the salivary gland. Int. J. Cancer, 124, 2855-2863.
32. Han,J. et al. (2009) Posttranscriptional crossregulation between Drosha and DGCR8. Cell, 136, 75-84.
33. Triboulet,R. et al. (2009) Post-transcriptional control of DGCR8 expression by the microprocessor. RNA, 15, 1005-1011.
34. Rodriguez,A. et al. (2004) Identification of mammalian microRNA host genes and transcription units. Genome Res., 14, 1902-1910.
35. Kataoka,N. et al. (2009) Functional association of the Microprocessor complex with spliceosome. Mol. Cell. Biol, 29, 3243-3254.
36. Merritt,W.M. et al. (2008) Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med., 359, 2641-2650.
37. Shibata,S. et al. (2006) Exportin-5 orthologues are functionally divergent among species. Nucleic Acids Res., 34, 4711-4721.
38. Rodriguez,M.S. et al. (2004) Nuclear export of RNA. Biol. Cell, 96, 639-655.
39. Lund,E. et al. (2004) Nuclear export of microRNA precursors. Science, 303, 95-98.
40. Revenkova,E. et al. (2004) Cohesin SMC1 beta is required for meiotic chromosome dynamics, sister chromatid cohesion and DNA recombination. Nat. Cell Biol., 6, 555-562.
41. Crawford,M. et al. (2009) MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem. Biophys. Res. Commun., 388, 483-489.
42. Cheng,S.Y. et al. (2008) Role and regulation of human tumor suppressor SUFU in Hedgehog signaling. Adv. Cancer Res., 101, 29-43.
43. Jain,M. et al. (2007) Role of GSTM3 polymorphism in the risk of developing esophageal cancer. Cancer Epidemiol. Biomarkers Prev., 16, 178-181.
44. Kesarwani,P. et al. (2009) Association of GSTM3 intron 6 variant with cigarette smoking, tobacco chewing and alcohol as modifier factors for prostate cancer risk. Arch. Toxicol., 83, 351-356.
45. Schnakenberg,E. et al. (2000) Susceptibility genes: GSTM1 and GSTM3 as genetic risk factors in bladder cancer. Cytogenet. Cell Genet., 91, 234-238.
46. Yu,K.D. et al. (2010) Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1. Breast Cancer Res. Treat, 121, 485-496.